Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23628700 | 0.80 | S1PR1 (0.37) | S1PR1S1PR3S1PR4ADORA3S1PR5 | |
| SCHEMBL23628680 | 0.80 | S1PR1 (0.36) | S1PR1S1PR3S1PR4ADORA3S1PR5 | |
| SCHEMBL23628689 | 0.78 | NOTUM (0.36) | S1PR1S1PR3NOTUMS1PR4ADORA3 | |
| SCHEMBL8990263 | 0.76 | S1PR1 (0.42) | S1PR1S1PR3NOTUMS1PR4ADORA3 | |
| SCHEMBL23628696 | 0.75 | AR (0.35) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL11920525 | 0.74 | ESR2 (0.47) | — | |
| SCHEMBL23628692 | 0.71 | IDO1 (0.41) | NOTUM | |
| SCHEMBL2502580 | 0.69 | IDO1 (0.38) | NOTUM | |
| SCHEMBL2037857 | 0.68 | NOTUM (0.39) | S1PR1NOTUM | |
| SCHEMBL13163540 | 0.68 | CA12 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210340104-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3847158-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| CN-112955431-A | Compounds useful for the treatment of autoimmune and inflammatory disorders | 艾尼纳制药公司 | 2021-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555015-B2 | Compounds useful in the treatment of autoimmune and inflammatory disorders | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR3 3/4885NOTUM 2014/4885 |
| US-20210340104-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR3 3/4885NOTUM 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.